A Study of Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD)
A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study Investigating Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD)
Sponsor: Asarina Pharma
Listed as NCT03697265, this PHASE2 trial focuses on Premenstrual Dysphoric Disorder and remains completed. Sponsored by Asarina Pharma, it has been updated 8 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 3 earlier versions
-
Jan 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Oct 2019 [monthly]
Recruiting PHASE2
First recorded
Apr 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Asarina Pharma
- Ergomed
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bad Homburg, Germany , Berlin, Germany , Elblag, Poland , Essen, Germany , Karlsruhe, Germany , Katowice, Poland , Krakow, Poland , Liverpool, United Kingdom , London, United Kingdom , Nuremberg, Germany and 2 more locations